Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

Company profile
Ticker
MYOV
Exchange
Website
CEO
Lynn Seely
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Myovant Sciences, Inc. • Myovant Holdings Ltd. • Myovant Sciences GmbH • Myovant Sciences Ireland Limited • Myovant Treasury, Inc. • Myovant Treasury Holdings, Inc. ...
MYOV stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
26 Jan 23
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 Jan 23
SC 13E3/A
Going private transaction (amended)
23 Jan 23
DEFM14A
Proxy related to merger
23 Jan 23
SC 13E3/A
Going private transaction (amended)
6 Jan 23
PRER14A
Preliminary revised proxy
6 Jan 23
SC 13E3
Going private transaction
8 Dec 22
PREM14A
Preliminary proxy related to merger
8 Dec 22
10-Q
2022 Q2
Quarterly report
26 Oct 22
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
26 Oct 22
Transcripts
MYOV
Earnings call transcript
2022 Q1
28 Jul 22
MYOV
Earnings call transcript
2021 Q4
10 May 22
MYOV
Earnings call transcript
2021 Q3
26 Jan 22
MYOV
Earnings call transcript
2021 Q2
26 Oct 21
MYOV
Earnings call transcript
2021 Q1
28 Jul 21
MYOV
Earnings call transcript
2020 Q4
11 May 21
MYOV
Earnings call transcript
2020 Q3
11 Feb 21
MYOV
Earnings call transcript
2020 Q2
12 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 256.76 mm | 256.76 mm | 256.76 mm | 256.76 mm | 256.76 mm | 256.76 mm |
Cash burn (monthly) | 32.02 mm | 17.59 mm | 18.81 mm | 13.52 mm | 34.30 mm | 22.49 mm |
Cash used (since last report) | 33.56 mm | 18.43 mm | 19.71 mm | 14.17 mm | 35.94 mm | 23.57 mm |
Cash remaining | 223.20 mm | 238.32 mm | 237.05 mm | 242.58 mm | 220.81 mm | 233.19 mm |
Runway (months of cash) | 7.0 | 13.5 | 12.6 | 17.9 | 6.4 | 10.4 |
Institutional ownership, Q3 2022
84.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 98 |
Opened positions | 30 |
Closed positions | 24 |
Increased positions | 26 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 1.46 bn |
Total shares | 82.29 mm |
Total puts | 601.60 k |
Total calls | 353.70 k |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
Sumitomo Chemical | 50.04 mm | $898.74 mm |
BBBOF BB Biotech | 6.12 mm | $95.32 mm |
BLVGF Bellevue | 5.91 mm | $106.19 mm |
Wellington Management | 5.47 mm | $98.16 mm |
JHG Janus Henderson | 3.95 mm | $71.01 mm |
Polar Capital | 1.95 mm | $34.98 mm |
BLK Blackrock | 1.19 mm | $21.31 mm |
Citadel Advisors | 970.11 k | $17.42 mm |
Vanguard | 821.84 k | $14.76 mm |
GS Goldman Sachs | 491.16 k | $8.82 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jan 23 | Arjona Ferreira Juan Camilo | Common Shares | Sell | Dispose S | No | No | 26.89 | 1,109 | 29.82 k | 246,684 |
18 Jan 23 | Marek David C | Common Shares | Sell | Dispose S | No | No | 26.89 | 8,037 | 216.11 k | 417,599 |
18 Jan 23 | Lauren Merendino | Common Shares | Sell | Dispose S | No | No | 26.89 | 2,008 | 54.00 k | 169,538 |
18 Jan 23 | Lang Matthew | Common Shares | Sell | Dispose S | No | No | 26.89 | 1,272 | 34.20 k | 354,303 |
4 Jan 23 | Lang Matthew | Common Shares | Sell | Dispose S | No | No | 26.9 | 2,779 | 74.76 k | 355,575 |
Press releases
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 Jan 23
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV
26 Jan 23
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
25 Jan 23
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, IMRA, MYOV, IAA
12 Jan 23
MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
11 Jan 23